N/A N=5 Transfemoral Socket Design and Muscle Function
Amputation
Primary: Residual Limb Hip Muscle Peak Torque at Baseline — 25.6; 14.9; 25.6; 13.1 newton-meters / kg*meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=184 Oscillatory Contributions to Working Memory and Attention
Young Adults
Primary: Behavioral Accuracy: Sub-study 1 — 86.3; 87.1 percentage of correct responses
Phase 2 N=24 Treg Modulation With CD28 and IL-6 Receptor Antagonists
Living-Donor Kidney Transplant · Kidney Transplant Recipients
Primary: The Proportion of Participants Who Remain Free of Biopsy-proven Acute T-cell Mediated or Antibody-mediated Rejection (as Defined by Banff Criteria) at 6 Months…
Phase 2 N=166 Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1%) — -1.1774; -1.9489; -0.5417; -1.5470 Change in FEV1 % predicted — p=0.3449
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 3 N=468 Phase III Study of ASP2151 in Herpes Simplex Patients
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 66.4; 69.5 Percentage of Participants — p=0.5086
N/A N=60 Sacroiliac (SI) Screws: The Effect of SI Screw Removal on Patient-Reported Pain and Functional Outcomes
Sacroiliac Joint · Pain · Pelvis
Primary: Post-operative Pain Within 6 Months After Iliosacral Screw Removal Using the Brief Pain Inventory (BPI) — 3.7; 4.7 units on a scale — p==0.57
Phase 2 N=124 Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
SARS-CoV-2 Infection, COVID19
Primary: Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2…
Phase 1 N=33 Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
Active Ethanol and Active Iomazenil · Active Ethanol and Placebo Iomazenil · Placebo Ethanol and Active Iomazenil
Primary: Biphasic Ethanol Effects Scale (BAES) — 3.767; 3.935; 3.813; 3.194 score on a scale
N/A N=418 Traditional Healer-initiated HIV Counseling and Testing in South Africa
HIV Infection
Primary: Feasibility of Completing HIV Testing Training — 16 Participants
Phase 2 N=41 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Primary: 1-year Progression-free Survival — 44; 33 percentage of participants
Phase 2 N=317 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose…
N/A N=60 Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
Stroke, Acute · Cerebral Infarction
Primary: Change in Functional Impairment, Jebsen Taylor Hand Function Test — 119; 181; -69; -64 seconds — p=0.88
Phase 4 N=44 Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Smallpox
Primary: AUC0-inf — 16300; 21600; 21000; 19500 ng*h/mL
N/A N=321 Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation
Heart Failure · Recurrent Atrial Fibrillation
Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001